The function of insulin receptor substrate-1 (IRS-1), a key molecule of insulin signaling, is modulated by phosphorylation at multiple serine/ threonine residues. Phorbol ester stimulation of cells induces phosphorylation of two inhibitory serine residues in IRS-1, i.e. Ser-307 and Ser-318, suggesting that both sites may be targets of protein kinase C (PKC) isoforms. However, in an in vitro system using a broad spectrum of PKC isoforms (␣, ␤1, ␤2, ␦, ⑀, , ), we detected only Ser-318, but not Ser-307 phosphorylation, suggesting that phorbol ester-induced phosphorylation of this site in intact cells requires additional signaling elements and serine kinases that link PKC activation to Ser-307 phosphorylation. As we have observed recently that the tyrosine phosphatase Shp2, a negative regulator ofinsulinsignaling,isasubstrateofPKC,westudiedtheroleofShp2inthis context. We found that phorbol ester-induced Ser-307 phosphorylation is reduced markedly in Shp2-deficient mouse embryonic fibroblasts (Shp2 ؊/؊ ) whereas Ser-318 phosphorylation is unaltered. The Ser-307 phosphorylation was rescued by transfection of mouse embryonic fibroblasts with wild-type Shp2 or with a phosphatase-inactive Shp2 mutant, respectively. In this cell model, tumor necrosis factor-␣-induced Ser-307 phosphorylation as well depended on the presence of Shp2. Furthermore, Shp2-dependent phorbol ester effects on Ser-307 were blocked by wortmannin, rapamycin, and the c-Jun NH 2 -terminal kinase (JNK) inhibitor SP600125. This suggests an involvement of the phosphatidylinositol 3-kinase/mammalian target of rapamycin cascade and of JNK in this signaling pathway resulting in IRS-1 Ser-307 phosphorylation. Because the activation of these kinases does not depend on Shp2, it is concluded that the function of Shp2 is to direct these activated kinases to IRS-1.
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Protein kinases C (PKCs), 2 a family of 12 structurally and functionally related serine/threonine kinases, have been shown to play a critical role in insulin resistance and type 2 diabetes (for review, see Ref. 1) . PKC activity is increased in insulin-sensitive tissues (muscle, liver) of diabetic patients (2, 3) . The PKC isoforms ␤1, ␤2 (4), ␣, ⑀, (5), ␦, and (6) are reported as potential candidates for negative regulation of insulin signaling. Activation of PKCs by hyperglycemia and phorbol ester inhibits insulin receptor tyrosine kinase activity (7, 8) and attenuates insulininduced tyrosine phosphorylation of downstream mediators of the insulin signaling pathway, such as insulin receptor substrate-1 (IRS-1) (9) . Upon activation of PKC, IRS-1 is phosphorylated on serine and threonine residues that have been shown to contribute to the development of insulin resistance (10, 11) .
Among several potential serine phosphorylation sites of IRS-1, serine 307 (rat IRS-1 Ser-307 corresponds to Ser-312 of human IRS-1) is a key regulatory site because phosphorylation of Ser-307 inhibits insulin-mediated activation of the phosphatidylinositol 3 (PI 3)-kinase and mitogen-activated protein kinase (MAPK) pathways by disturbing the interaction of IRS-1 with the insulin receptor (12) . c-Jun NH 2 -terminal kinase (JNK) (13) and inhibitor of B kinase-␤ (IKK-␤) (14) have been described to phosphorylate IRS-1 at Ser-307. Recently, it was reported that phorbol ester-stimulated PKC activation promotes phosphorylation of IRS-1 at Ser-307 (15, 16) . However, we and others have recently shown using in vitro phosphorylation assays that rat IRS-1 Ser-318 (corresponding to Ser-323 of human IRS-1), but not Ser-307, serves as a major PKC phosphorylation site (17, 18) . Thus, PKC-dependent Ser-307 phosphorylation in intact cells is probably not direct and requires further downstream effectors.
One candidate mediator is the cytoplasmic protein-tyrosine phosphatase Shp2, which was shown previously (19, 20) to be upstream of potential IRS-1 serine/threonine kinases, such as the MAPK family members extracellular signal-regulated kinases 1 and 2 (ERK1/2) (21, 22) . Furthermore, Shp2 mRNA, protein, and activity were shown to be increased in liver and skeletal muscle of animal models of insulin resistance and diabetes (23, 24) . In 3T3-L1 fibroblasts, overexpression of wild-type Shp2 impairs insulin-stimulated tyrosine phosphorylation of IRS-1 as well as PI 3-kinase activation, resulting in decreased glycogen synthesis (25) . Structurally, Shp2 is characterized by a catalytic subunit at the carboxyl terminus and two Src homology 2 (SH2) domains at the amino terminus (26) . With its SH2 domains, Shp2 binds tyrosine-phosphorylated proteins including components of the insulin signaling pathway, such as the insulin receptor (27) , IRS-1 (28), and IRS-2 (29) . Therefore, Shp2 may modulate insulin-dependent pathways through direct interaction with the insulin receptor (30) and the insulin receptor substrates (31) . Furthermore, the insulin-like actions of vanadate (32) have been shown to be partly mediated by inhibition of Shp2 (33) . Treatment with vanadate reverses the effects of hyperglycemia on insulin receptor and IRS-1 phosphorylation status by blocking Shp2 association with IRS-1 (34).
Based on the ability of Shp2 to regulate insulin signaling negatively and our recent finding that Shp2 is a substrate of classical and novel PKC isoforms (35) , we investigated in this study whether Shp2 is a mediator of PKC-induced phosphorylation of Ser-307 in IRS-1.
EXPERIMENTAL PROCEDURES
Materials-Cell culture reagents and fetal calf serum were from Cambrex Bioscience (Verviers, Belgium). 12-O-Tetradecanoylphorbol-13-acetate (TPA), aprotinin, phenylmethylsulfonyl fluoride, Na 3 VO 4 , Triton X-100, dimethyl sulfoxide, dithiothreitol, anisomycin, bisindolylmaleimide I, wortmannin, as well as secondary anti-mouse, antirabbit, and anti-goat antibodies were purchased from Sigma. Reagents for SDS-PAGE and Western blotting were from Roth (Karlsruhe, Germany) and Bio-Rad. Geneticin was from Invitrogen, enhanced chemiluminescence reagent and nitrocellulose were from Amersham Biosciences, and gel blotting papers were from Schleicher & Schuell. Recombinant human insulin was from Lilly (Indianapolis). Recombinant human tumor necrosis factor-␣ (TNF-␣) was from TEBU (Offenbach, Germany), SP600125 was from Apotech (San Diego), PD98059 was from Alexis Biochemical (Carlsbad, CA), and farnesylthiosalicylic acid was from Biomol (Plymouth Meeting, PA). SB20358, 15-deoxyprostaglandin J2 (15dPGJ2), FTI-277, rapamycin, and a JNK Activity Immunoassay Kit were from Calbiochem. D-myo-Phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P 2 ) was from Echelon Biosciences (Salt Lake City, UT). Thin layer chromatography plates (Silica Gel 60) were from Merck. X-AR 5 film was from Kodak.
The rabbit polyclonal IRS-1 phosphoserine 307-specific antibody was a gift from Dr. Morris F. White (Joslin Diabetes Center, Boston, MA). The mouse monoclonal IRS-1 antibody and the rabbit polyclonal IRS-1 phosphoserine 318-specific antibody were produced in our laboratory. The rabbit polyclonal Shp2 (NH 2 terminus) antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). The rabbit polyclonal Akt phosphothreonine 308-specific antibody, the rabbit polyclonal Akt antibody, the rabbit polyclonal c-Jun phosphoserine 73-specific antibody, the rabbit polyclonal c-Jun antibody, the rabbit polyclonal p70S6 kinase phosphothreonine 389-specific antibody, and the rabbit polyclonal p70S6 kinase antibody were purchased from Cell Signaling Technology (Beverly, MA). Protein G-Sepharose CL-4B and [␥-32 P]ATP were purchased from Amersham Biosciences. All HPLC-grade solvents were obtained from Merck.
Purification and in Vitro Phosphorylation of GST-IRS-1 N2 with PKC Isoforms-The glutathione S-transferase (GST) fusion protein with the amino-terminal fragment of rat IRS-1 (IRS-1 N2 ; amino acids 265-522; size 53.8 kDa), was generated as described previously (18) . In brief, the fragment was ligated to GST and cloned into the pGEX-2T vector (Amersham Biosciences). The DNA encoding this region of IRS-1 was synthesized by PCR using rat IRS-1 cDNA as template and pairs of oligonucleotide primers that contain appropriate restriction sites bordering these fragments (36) . For mutation of the codon for amino acid position 318 serine to alanine, base substitutions were made by oligonucleotide-mediated mutagenesis. The mutagenesis upstream primer used was 5Ј-GGTGGGAAACCAGGTGCCTTCAGGGTGCGTGC-C-3Ј with the wild-type IRS-1 expression vector as template. Positive clones were verified by sequencing. The PCR products were isolated, digested with appropriate restriction enzymes, and subcloned into pGEX-2T vectors, which were used to transform Escherichia coli BL21. The fusion protein was expressed and purified by affinity chromatography. The in vitro phosphorylation assays were performed at 30°C for 90 min with 1 nmol of the isolated GST-IRS-1 N2 protein fragments (wildtype and S318A mutant), which were phosphorylated in vitro by recombinant PKC isoforms ␣,␤1, ␤2, ⑀,, and (Calbiochem) in 55 mMHEPES, pH 7.5, 1.25 In-gel Protein Digestion and Reversed Phase HPLC Peptide Separation-The GST-IRS-1 N2 protein was excised and in-gel digested as described previously (37) . Peptides eluted from the polyacrylamide matrix were separated on a 100 ϫ 2.0 (inner diameter) mm C4/C18 reversed phase column (Grom, Herrenberg, Germany) using a 10A HPLC system (Shimadzu, Duisburg, Germany) equipped with a Uvichord 2215 UV-Detector (Amersham Biosciences). The gradient program used was: 0-5 min 3% B, 5-10 min 15% B, and 10-80 min 60% B, where A was 0.025% trifluoroacetic acid in water and B was 0.023% trifluoroacetic acid, 80% acetonitrile in water at a flow rate of 250 l/min. Elution was monitored at 214 nm. Collected fractions (1 min cut) were analyzed in a Trilux 1450 MicroBeta Plus ␤-counter (PerkinElmer Life Sciences).
Cell Culture-Shp2 knock-out mouse embryonic fibroblasts (MEF Shp2 Ϫ/Ϫ ), kindly provided by Dr. Tony Pawson, Toronto, Canada, and the human cell line BOSC 23 were maintained in Dulbecco's modified Eagle's medium (1 g/liter glucose), supplemented with 10% fetal calf serum. Packaging cells GPϩE86 were grown in Dulbecco's modified Eagle's medium (4.5 g/liter glucose) containing 10% fetal calf serum.
Generation of Recombinant Retroviruses-The cDNAs for Shp2, the serine-to-alanine mutant Shp2 S576A/S591A, and the phosphatasenegative Shp2 (C459A), described previously (35), were excised from the cytomegalovirus immediate early promoter-based expression plasmid pRK5 as EcoRI/XhoI fragments and ligated into EcoRI/XhoI-digested retroviral expression vector pLXSN (38) . After analyzing the sequences of the plasmid constructs by sequencing, plasmid DNA was prepared using a Qiagen Plasmid Kit. To receive retroviral stocks by transient transfection (39) , BOSC 23 cells were transfected with each of these constructs. To increase the titer of the recombinant retroviruses, 10 5 exponentially growing packaging cells GPϩE86/6-well plate were incubated with supernatants of BOSC 23 cells containing the recombinant retroviruses for 12 h at 37°C, 5% CO 2 , and in the presence of 8 g/ml Polybrene. Virus-containing medium was then removed, and cells were grown for selection in medium containing 750 g/ml Geneticin for 2-3 weeks.
Retrovirus-mediated Gene Transfer-10 5 MEF Shp2 Ϫ/Ϫ cells/6-well plate were incubated with the supernatants of retrovirus-expressing GPϩE86 cells in the presence of 8 g/ml Polybrene for 24 h at 37°C, 5% CO 2 . Virus-containing medium was then removed, and cells were selected in medium containing 750 g/ml Geneticin for 2 weeks. Geneticin-resistant clones were transferred to 10-cm dishes and analyzed for the expression of the transduced gene. Stimulation and Cell Lysis-MEF cells were stimulated with 100 nM TPA for 10 to 120 min, or 100 nM insulin, 5 nM TNF-␣, 25 mM glucose, 25 g/ml anisomycin, or 10 M PtdIns(3,4)P 2 for 30 min at 37°C. In some experiments, cells were preincubated with 20 M JNK inhibitor SP600125, 1 M p38 kinase inhibitor SB203580, 20 M MAPK/ERK kinase (MEK) 1 inhibitor PD98059, 500 nM PKC inhibitor bisindolylmaleimide I, 15 M IKK-␤ inhibitor 15dPGJ2, 10 and 100 nM PI 3-kinase inhibitor wortmannin, or 25 nM mammalian target of rapamycin (mTOR) inhibitor rapamycin each for 10 min at 37°C, with 25 M Ras inhibitor farnesylthiosalicylic acid or 1 M Ras inhibitor FTI-277 each for 24 h at 37°C. After washing with phosphate-buffered saline, the cells were lysed (500 l/10-cm diameter dish) with ice-cold lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 10% glycerol, 1% Triton X-100) containing a protease/phosphatase inhibitor mix (1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 100 mM NaF, 10 mM Na 4 P 2 O 7 , 2 mM Na 3 VO 4 ). Cell lysates were cleared by centrifugation at 12,000 ϫ g for 10 min at 4°C.
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Western Blotting-After separation by SDS-PAGE (100 g of total protein/lane), proteins were transferred to nitrocellulose membranes by semi-dry electroblotting. Membranes were incubated in gelatin buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris, 0.05% Triton X-100, and 0.25% gelatin, pH 7.4) for 1 h at room temperature, probed with the appropriate primary antibody overnight at 4°C, washed three times with gelatin buffer followed by incubation with peroxidase-conjugated secondary antibody for 1.5 h at room temperature. Signals were detected by enhanced chemiluminescence.
PI 3-Kinase Assay-PI 3-kinase assays were performed as described by Morgan et al. (40) , with some modifications. Briefly, PI 3-kinase was immunoprecipitated from MEF cell lysates. Immunoprecipitates were washed twice in phosphate-buffered saline, 1% Nonidet P-40, and 100 mol/liter Na 3 VO 4 ; twice in 500 mmol/liter LiCl, 100 mmol/liter TrisHCl, pH 7.5, and 100 mmol/liter Na 3 VO 4 ; and twice in 10 mmol/liter Tris-HCl, pH 7.5, 100 mmol/liter NaCl, 1 mmol/liter EDTA, and 100 mol/liter Na 3 VO 4 . The beads were resuspended in 25 l of 60 mmol/ liter Tris-HCl, pH 7.5, 300 mmol/liter NaCl, 12 mmol/liter MgCl 2 , and 12.5 l of phosphatidylinositol (1 mg/ml). The kinase reaction was started by adding 12.5 l of 40 mol/liter ATP containing 10 Ci [␥-
32 P]ATP, and samples were incubated for 20 min at room temperature. The reaction was stopped by the addition of 150 l of 1 N HCl. Lipids were extracted once with 450 l of chloroform:methanol (1:1, v/v), and the phospholipid-containing organic phase was resolved on thin layer chromatography plates and developed in chloroform:methanol:acetone:glacial acetic acid:water (40:13:15:12:7, v/v). Thin layer chromatography plates were dried and exposed on film.
JNK Activity Immunoassay-JNK activity immunoassay was performed according to the manufacturer's protocol. In brief, JNK was immunoprecipitated from MEF cell lysates, immunoprecipitates were washed three times, the kinase reaction was started by adding c-Jun protein and an ATP mixture, and samples were incubated for 25 min at 30°C. Proteins were separated by SDS-PAGE, and Western blotting was performed as described above using a c-Jun phospho-specific antibody.
Densitometry and Statistical Analysis-For quantification of signal intensity of phospho-specific immunoblots, the EasyWin32 Herolab Software was used. Densitometric data obtained from phospho-specific signals were normalized to the densitometric values obtained from the corresponding immunoblots detecting protein expression. At least five independent experiments were performed to obtain mean values Ϯ S.E. A one-way analysis of variance with Bonferroni's post hoc multiple comparison test was used to detect differences between the groups. p Ͻ 0.05 was considered to be statistically significant.
RESULTS
In Vitro Phosphorylation of IRS-1
N2 by Phorbol Ester-inducible PKC Isoforms-Based on mass spectrometry, we and others have recently identified Ser-318 as a major in vitro phosphorylation site of PKC isoforms and ␦ in the IRS-1 N2 fragment (rat IRS-1 sequence comprising amino acids 265-522) (17, 37) . However, we did not detect Ser-307 phosphorylation. Therefore, we tested whether other phorbol esterinducible PKC isoforms, such as PKC-␣, -␤1, -␤2, -⑀, -, and , are able to phosphorylate Ser-307 directly in the same experimental setting. Using these isoforms in recombinant form, the fragment IRS-1 N2 was again phosphorylated at Ser-318, but not at Ser-307 (data not shown). From these results, we conclude that IRS-1 Ser-307 is not a direct substrate for PKC and that phorbol ester-induced phosphorylation of this site in intact cells requires additional signaling elements.
Involvement of Shp2 in TPA-induced Phosphorylation of IRS-1 Ser-307-Because we have recently observed that the tyrosine phosphatase
Shp2 is a substrate of PKC, we studied the role of Shp2 in this context. In mock-transfected MEF Shp2 Ϫ/Ϫ cells, TPA only weakly stimulated Ser-307 phosphorylation of IRS-1. However, after reexpression of wild-type Shp2, phosphorylation of Ser-307 was enhanced markedly (Fig. 1A) . By contrast, there was no difference in TPA-induced Ser-318 phosphorylation between mock-transfected MEF Shp2 Ϫ/Ϫ cells and Shp2-reexpressing cells (Fig. 1B) . These data suggest that Shp2 is specifically involved in TPA-induced phosphorylation of Ser-307. To confirm the involvement of PKC, TPA-treated MEF cells reexpressing wild-type Shp2 were preincubated with the PKC inhibitor bisindolylmaleimide I. This treatment caused markedly diminished TPA-induced Ser-307 phosphorylation (Fig. 2) . In MEF cells transfected with human wild-type Shp2, not only stimulation with the PKC activator TPA (100 nM), but also treatment with insulin (100 nM), TNF-␣ (5 nM), and high glucose (25 mM), resulted in increased IRS-1 Ser-307 phosphorylation. These phosphorylation events were diminished in MEF Shp2 Ϫ/Ϫ cells (Fig. 3, A and B) . However, only the TPA-and TNF-␣-induced Ser-307 phosphorylation signals significantly depended on the presence of Shp2 (p Ͻ 0.05, Bonferroni's post hoc test, n ϭ 5, Fig. 3B ). In conclusion, TPA-and TNF-␣-induced phosphorylation of IRS-1 Ser-307 requires Shp2, whereas this protein-tyrosine phosphatase is not involved in PKC-stimulated Ser-318 phosphorylation. 
Role of Serine Residues 576 and 591 and the Phosphatase Activity of Shp2 in TPA-stimulated IRS-1 Ser-307 Phosphorylation-Because
Shp2 is phosphorylated at serine residues 576 and 591 by PKC (35), we tested the involvement of these phosphorylation sites in TPA-stimulated phosphorylation of IRS-1 Ser-307. Furthermore, we tested the requirement of phosphatase activity in TPA-induced IRS-1 phosphorylation at Ser-307. To this end, we introduced mutant forms of Shp2, i.e. the double mutant S576A/S591A and the phosphatase-negative mutant C459A, into MEF Shp2 Ϫ/Ϫ cells. In contrast to the mock-transfected
MEF Shp2
Ϫ/Ϫ cells, all Shp2 constructs (wild-type, double mutant S576A/S591A, and phosphatase-negative form) promoted significant TPA-induced Ser-307 phosphorylation. However, there was no significant difference in the degree of TPA-dependent Ser-307 phosphorylation between wild-type and mutant Shp2 forms (Fig. 4, A and B) . This suggests that neither the PKC phosphorylation sites nor the phosphatase activity is necessary for Shp2 mediation of PKC-induced IRS-1 Ser-307 phosphorylation.
Role of JNK in Shp2-dependent IRS-1 Ser-307
Phosphorylation-JNK and IKK-␤ have been described as phosphorylating IRS-1 at Ser-307 (13, 14) . Accordingly, incubation of MEF cells with the specific JNK activator anisomycin induced a marked IRS-1 Ser-307 phosphorylation both in wild-type Shp2-expressing cells and in mock-transfected cells (Fig.  5A) . Preincubation with the JNK inhibitor SP600125 markedly decreased TPA-induced IRS-1 Ser-307 phosphorylation in MEF cells reexpressing wild-type Shp2, whereas incubation with the IKK-␤ inhibitor 15dPGJ2 did not alter this phosphorylation (Fig. 5B ). This suggests a critical role of JNK, but not of IKK-␤, in Shp2-regulated phosphorylation of Ser-307 in IRS-1. Testing the involvement of MAPK, such as ERK1/2 and p38, we found that preincubation with the p38 inhibitor SB203580 or with the MEK1 kinase inhibitor PD098059, respectively, left the phosphorylation of IRS-1 Ser-307 unaffected (Fig. 5B) , suggesting that p38 and ERK1/2 are not involved in Shp2-mediated phosphorylation of Ser-307 in IRS-1.
Role of the PI 3-Kinase/mTOR Pathway in Shp2-dependent IRS-1 Phosphorylation at Ser-307-Because it is known that Ras and PI 3-kinase can activate JNK (41, 42), we tested their involvement in Shp2-dependent phosphorylation of Ser-307 in IRS-1. Preincubation of MEF cells reexpressing wild-type Shp2 with the farnesylation inhibitors farnesylthiosalicylic acid and FTI-277 had no influence on TPA-induced Ser-307 phosphorylation in IRS-1 (data not shown). By contrast, pretreatment with the PI-3 kinase inhibitor wortmannin dose-dependently decreased phorbol ester-stimulated IRS-1 phosphorylation at Ser-307 (Fig. 6A) , suggesting a critical role of PI-3 kinase, but not of Ras, in Shp2-regulated IRS-1 Ser-307 phosphorylation. Treatment with the PI 3-kinase product PtdIns(3,4)P 2 strongly increased IRS-1 Ser-307 phosphorylation both in MEF cells transfected with wild-type Shp2 or mock- 
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transfectants, confirming the importance of PI-3 kinase in IRS-1 phosphorylation on Ser-307 (Fig. 6B) . To test whether mTOR, a well known downstream target of PI 3-kinase and a potential IRS-1 kinase (43) , is involved in Shp2-dependent IRS-1 Ser-307 phosphorylation, TPAstimulated Shp2-reexpressing cells were pretreated with rapamycin. As depicted in Fig. 7 , rapamycin pretreatment abolished TPA-induced Ser-307 phosphorylation, providing evidence that mTOR is indeed a component of this signaling pathway. Furthermore, PtdIns(3,4)P 2 -induced Ser-307 phosphorylation was blocked by rapamycin as well (Fig. 7) . This suggests that the PI 3-kinase/mTOR axis, acting in line or in parallel with JNK, is necessary for Shp2-dependent phosphorylation of Ser-307 in IRS-1.
Activation of JNK, PI 3-Kinase, and mTOR upon Stimulation with TPA and TNF-␣-As so far the exact role of Shp2 in PKC-dependent Ser-307 phosphorylation of IRS-1 remained unclear, we asked whether Shp2 regulates the activation of JNK, PI 3-kinase, and mTOR. The JNK activity immunoassay showed a TPA-induced phosphorylation of c-Jun in wild-type Shp2-expressing cells as well as in MEF Shp2 Ϫ/Ϫ (Fig. 8A ).
Incubation with TPA induced an Akt Thr-308 phosphorylation and p70S6 kinase (S6K) Thr-389 phosphorylation both in wild-type Shp2-expressing cells and in MEF Shp2 Ϫ/Ϫ cells (Fig. 8B ). After stimulation with TNF-␣, there was also an Akt Thr-308 phosphorylation and S6K Thr-389 phosphorylation as well as a phosphorylation of c-Jun in the JNK activity immunoassay both in wild-type Shp2-expressing cells and in MEF Shp2 Ϫ/Ϫ cells (data not shown). The PI 3-kinase assay did not show a difference in PI 3-kinase activity after stimulation with TPA and TNF-␣ between wild-type Shp2-expressing cells and mock-transfected cells (data not shown). These results suggest that activation of JNK, PI-3 kinase, and mTOR after TPA and TNF-␣ treatment was independent of the presence of Shp2, whereas directing these kinases to the end point IRS-1 Ser-307 phosphorylation requires the presence of Shp2.
DISCUSSION
Previous studies have identified serine residues 307 and 318 in IRS-1 as targets of several protein kinases, among these also members of the PKC family. In the present study we show that the PKC activators TPA and TNF-␣ induce phosphorylation of both serine residues. However, only the phosphorylation of Ser-307 depended on the presence of pro- . A, JNK activity was measured using a JNK activity immunoassay. JNK was immunoprecipitated from MEF cell lysates, and the kinase reaction was started by adding recombinant c-Jun protein and an ATP mixture (for further details, see "Experimental Procedures"). Proteins were separated by SDS-PAGE, and Western blotting was performed using a c-Jun phospho-specific antibody. B, the activities of PI 3-kinase and mTOR were analyzed using phospho-specific antibodies of their substrates. Representative immunoblots are shown. tein-tyrosine phosphatase Shp2. High glucose and insulin, also known to activate PKC, stimulated Ser-307 phosphorylation as well but did not reveal clear Shp2 dependence. The reason for this discrepancy is unknown but might reflect the existence of alternative Shp2-independent PKC signaling pathways resulting in IRS-1 Ser-307 phosphorylation. This is further evidenced by the finding that, even in the complete absence of Shp2, residual Ser-307 phosphorylation signals are seen with all external stimuli tested (Fig. 3A) .
Neither the phosphatase activity of Shp2 nor its serine residues 576 and 591, which have been described previously to be phosphorylated by PKC (35) are required for phorbol ester-induced Ser-307 phosphorylation. The observation that Shp2 can modulate signaling independently of its phosphatase activity is in agreement with previous studies demonstrating that Shp2 functions as an adaptor or scaffolding molecule that brings into close proximity upstream regulators, such as growth factor receptors, and downstream effectors, such as Ras (44, 45) , Src (46) , and PI 3-kinase (47, 48) . In accordance with this, Shp2 has previously been shown to have a phosphatase-independent adaptor function in insulin receptor/IRS-1 interaction as well allowing the formation of a multiprotein signaling complex (49) . Furthermore, Noguchi et al. (20) demonstrated that upon insulin stimulation, a catalytically inactive mutant of Shp2 did not affect PI 3-kinase activation, but attenuated MAPK activation. By contrast, Ugi et al. (51) reported that expression of a mutant Shp2 that lacked the entire catalytic domain inhibited insulininduced PI 3-kinase activity. The detected differences may be explained by the different tertiary structures of the Shp2 mutants. Although we as well as Noguchi et al. (20) expressed a catalytically inactive Shp2 that was point mutated at cysteine 459, a highly conserved cysteine residue in all tyrosine phosphatases which is crucial for catalytic activity (52), Ugi et al. (51) used a Shp2 that consisted only of the two SH2 domains and lacked the complete catalytic domain. Therefore, the interaction of this truncated Shp2 mutant with binding partners may be disturbed, or unspecific associations with nonphysiological binding partners may occur. We propose that Shp2 as a molecular linker brings together PKC and its downstream mediators of IRS-1 Ser-307 phosphorylation.
Consistent with recent studies (13, 16), we have found that PKCinduced Shp2-dependent IRS-1 Ser-307 phosphorylation depends on JNK, a well known downstream effector of TNF-␣. Other kinases that have been described to phosphorylate IRS-1 such as IKK-␤ (14) and MAPK (53) do not seem to be involved in this phosphorylation event in our cell system. The exact mechanism of JNK activation is still unclear. Several potential upstream activators of JNK, such as the small GTPbinding protein Ras (41) and PI 3-kinase (42), have been described. However, our data do not indicate a critical role of Ras in Shp2-dependent IRS-1 Ser-307 phosphorylation. By contrast, we found that PI 3-kinase and mTOR are involved in Ser-307 phosphorylation, consistent with previous inhibitor studies showing that inhibition of PI-3 kinase or mTOR decreased insulin-induced Ser-307 phosphorylation in IRS-1 (43, 50, 53) .
TPA and TNF-␣ treatment induced a phosphorylation of AKT and p70S6K, known substrates of PI 3-kinase and mTOR respectively, in Shp2-wild type expressing cells as well as in MEF Shp2
Ϫ/Ϫ cells. The PI 3-kinase assay as well as the JNK activity immunoassay did also not show differences between Shp2 wild-type expressing cells and MEF Shp2 Ϫ/Ϫ cells, indicating that activation of these kinases by phorbol ester was independent of the presence of Shp2. Because TPA-and TNF-␣-induced IRS-1 Ser-307 phosphorylation required Shp2, we suppose that Shp2, probably via its scaffolding function, mediates specificity of JNK, PI 3-kinase, and mTOR toward IRS-1 Ser-307. It remains confusing that JNK and mTOR activated indirectly by TPA require Shp2 as scaffold protein to phosphorylate IRS-1 Ser-307, whereas the same kinases activated directly by anisomycin or PtdIns(3,4)P 2 , respectively, do not depend on the presence of Shp2. This discrepancy is indeed difficult to explain. On the other hand, as already discussed above, we detect weak TPA-induced phosphorylation of IRS-1 Ser-307 even in the absence of Shp2 (Figs. 1A and 3, A and B) , and this suggests that alternative Shp2-independent pathways exist. It is conceivable that anisomycin and PtdIns(3,4)P 2 are strong activators of these pathways. Why anisomycin and PtdIns(3,4)P 2 activate them more efficiently than TPA cannot be explained by our data but might be the result of differences in the mode of activation (cellular localization, efficiency and duration of activation, and complex formation) of the kinases by these pharmacological stimuli.
In conclusion, we have found that phorbol ester-and TNF-␣-induced phosphorylation of Ser-307 in IRS-1 is not a direct PKC-mediated event but depends on the presence of Shp2. Future experiments will evaluate the relevance of these findings in vivo.
